Field Medical, Inc., a clinical-stage medical technology company developing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, presented late-breaking clinical trial data from the first-in-human Field PULSE study at the 31st International AF Symposium, held February 5–7, 2026, in Boston.
The Field PULSE study evaluated a novel high-voltage, sub-second pulsed field waveform delivered via the company’s FieldForce™ ablation system and catheter—a focal, contact-sensing catheter that enables instantaneous point-by-point ablation without requiring prolonged tissue-catheter contact.
The late-breaking presentation highlighted key findings:
- Instantaneous energy delivery: Lesions created in less than 200 milliseconds, enabling rapid point-by-point ablation.
- Procedural efficiency: Median time for bilateral pulmonary vein isolation was 12.5 minutes, with the fastest case completed in 7.7 minutes.
- Pulmonary vein isolation durability: Remapping showed progressive improvement with waveform optimization, achieving 94.2% per vein and 84.6% per patient.
- Safety profile: No device-related serious adverse events, no acute kidney injury, no phrenic nerve palsy, and no clinically relevant hemolysis. In 14 patients evaluated by cerebral MRI, no silent cerebral lesions (DWI+/FLAIR+) were observed.
Vivek Y. Reddy, M.D., principal investigator of Field PULSE and electrophysiologist at Mount Sinai, New York, stated that eliminating the need for sustained tissue contact allows effective point-by-point ablation and individualized lesion sets. The approach preserves the flexibility physicians expect from focal ablation while delivering the procedural efficiency associated with PFA technologies.
These results extend Field Medical’s clinical evidence for high-voltage focal PFA beyond ventricular arrhythmias to atrial fibrillation (AF) treatment. Combined with previously reported six-month human data on ventricular tachycardia (VT), they support the development of a versatile platform for ablation in all cardiac chambers, targeting both atrial and ventricular substrates while maintaining procedural efficacy.
Steven Mickelsen, M.D., founder and chief technology officer of Field Medical, emphasized that the technology addresses core limitations of existing methods by delivering each ablation point in a fraction of a second, reducing dependence on prolonged catheter stability and minimizing the impact of cardiac motion.
Additional presentations at the symposium included:
- A scientific session on February 6 (7:30–8:30 a.m.) titled “Maximizing Lesion Depth Using High-Voltage PFA Waveforms,” presented by Kenneth Ellenbogen, M.D.
- A case transmission session on February 7 (7:30–9:30 a.m.) demonstrating high-voltage FieldForce PFA catheter ablation for AF, presented by Vivek Reddy, M.D.
The FieldForce™ ablation system incorporates proprietary FieldBending™ technology to deliver targeted high-intensity electric fields using a novel pulsed energy delivery strategy. Designed for both atrial and ventricular ablation, it serves as a universal cardiac ablation platform focused on procedural efficiency and targeted treatment.
Field Medical, founded in 2022 by Dr. Steven Mickelsen, is advancing PFA solutions for complex cardiac arrhythmias. In 2024, the company received FDA Breakthrough Device Designation and was accepted into the FDA’s TAP Pilot Program for its ventricular tachycardia indication. The VCAS trial was published in Circulation in October 2025.
The FieldForce™ ablation system is an investigational device limited by federal law to investigational use.
The announcement was issued by Field Medical, Inc. on February 6, 2026.
